摘要
目的探讨白蛋白结合型紫杉醇与紫杉醇脂质体治疗复发性卵巢癌的疗效及安全性差异。方法以2013年1月至2016年6月榆林市第二医院和北京大学第一医院收治的60例复发性卵巢癌患者为研究对象,根据入院先后顺序分为观察组和对照组,每组30例。对照组给予紫杉醇脂质体联合奈达铂治疗,观察组给予白蛋白结合型紫杉醇联合奈达铂治疗。比较2组治疗2个疗程后的临床疗效、治疗前后生活质量及不良反应发生情况。结果治疗2个疗程后,观察组的总有效率高于对照组,但差异无统计学意义(P>0.05);观察组的CR率显著高于对照组(P<0.05)。治疗后观察组和对照组的KPS评分均较治疗前显著升高(P<0.05),且观察组治疗后的KPS评分显著高于对照组(P<0.05)。观察组的白细胞减少、周围神经炎(即0级)的发生率显著高于对照组(P<0.05),但恶心呕吐、腹泻的Ⅲ~Ⅳ级发生率显著低于对照组(P<0.05)。结论与紫杉醇脂质体比较,白蛋白结合型紫杉醇治疗复发性卵巢癌的临床疗效更高,可显著改善患者的生活质量,且不良反应少,安全性较高。
Objective To evaluate the efficacy and safety of albumin bound paclitaxel and paclitaxel liposome for recurrent ovarian cancer. Methods 60 patients with recurrent ovarian cancer were selected as the research object. According to the admission date,60 patients with recurrent ovarian cancer were divided into the observation group （n = 30） and the control group （ n = 30）. The control group were treated using paclitaxel liposome combined with nedaplatin, the observation group was treated with albumin bound paclitaxel combined with nedaplatin. The clinical curative effect after 2 courses of treatment, quality of life before and after treatment and the incidence of adverse reactions of the 2 groups were compared. Results After 2 courses treatment, the total effective rate of the observation group was higher than the control group, but the difference was not statistically significant （ P 〉 0.05 ）. The CR of the observation group was significantly higher than the control group （ P 〈 0.05 ）. After treatment, the KPS scores of observation group and the control group were significantly higher than before treatment （ P 〈 0.05 ）, and the observation group was significantly higher than the control group （ P 〈 0.05 ）. The white blood cells of the observation group were decreased, and the incidence rate of peripheral neuritis （ grade 0 ） was significantly higher than the control group （ P 〈 0.05 ）. Nausea and vomiting, diarrhea grade of the observation group were significantly lower than that of the control group （ P 〈 0.05 ）. Conclusion Compared with paelitaxel liposome, albumin bound paclitaxel is more effective in the treatment of recurrent ovarian cancer, and can significantly improve the quality of life of patients. And albumin bound paclitaxel for recurrent ovarian cancer has less adverse reactions and high safety.
出处
《实用癌症杂志》
2018年第3期507-510,共4页
The Practical Journal of Cancer
关键词
卵巢癌
复发
紫杉醇
疗效
安全性
Ovarian cancer
Recurrence
Paclitaxel
Efficacy
Safety
